Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CHKA | P35790 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476810 | 1.00 | CA2 (0.56) | CA2CHKACA12CA1CA9 | |
| SCHEMBL24199321 | 0.98 | CA2 (0.54) | CA2CHKACA12CA1CA9 | |
| SCHEMBL24208157 | 0.95 | CA2 (0.48) | CA2CHKACA12CA1CA9 | |
| Pyrrolidine SCHEMBL2453664 | 0.93 | CA2 (0.52) | CA2CHKACA12CA1CA9 | |
| SCHEMBL603099 | 0.91 | — | — | |
| SCHEMBL5433 | 0.91 | — | — | |
| SCHEMBL15689312 | 0.88 | CA2 (0.52) | CA2CHKACA12CA1CA9 | |
| SCHEMBL9286350 | 0.88 | CA2 (0.52) | CA2CHKACA12CA1CA9 | |
| Potassium SCHEMBL30601762 | 0.88 | CA2 (0.52) | CA2CHKACA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL2855578 | 0.88 | CA2 (0.52) | CA2CHKACA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406439-B | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-118406439-A | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-115093794-B | Polysilicon polishing composition and application thereof | 万华化学集团电子材料有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-115093794-A | Polysilicon polishing composition and application thereof | 万华化学集团电子材料有限公司 | 2022-09-23 | — | — | CN | claimed |
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| EP-3489238-A1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | Dart NeuroScience (Cayman) Ltd (KY) | 2019-05-29 | — | — | EP | claimed |
| EP-2861603-B1 | 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-19 | — | — | EP | claimed |
| US-20170218162-A1 | RECYCLING PROCESS | WORN AGAIN TECHNOLOGIES LIMITED (GB) | 2017-08-03 | — | — | US | claimed |
| EP-3172267-A1 | RECYCLING PROCESS | Worn Again Footwear And Accessories Limited (GB) | 2017-05-31 | — | — | EP | claimed |
| EP-2861605-B1 | 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2017-05-03 | — | — | EP | claimed |
| US-9499562-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-11-22 | — | — | US | claimed |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2016-02-04 | — | — | US | claimed |
| WO-2016012755-A1 | RECYCLING PROCESS | WORN AGAIN FOOTWEAR AND ACCESSORIES LIMITED (GB) | 2016-01-28 | — | — | WO | claimed |
| CN-104876893-A | Substituted-homopiperzine dithiocarbamic acid bismuth complexes, and medicinal salts, preparation methods and antitumor application thereof | UNIV NANYANG NORMAL | 2015-09-02 | — | — | CN | claimed |
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-06-11 | — | — | US | claimed |
| EP-2861603-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE - 5 - (6H) - ONE COMPOUNDS | Dart NeuroScience (Cayman) Ltd (KY) | 2015-04-22 | — | — | EP | claimed |
| EP-2861605-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2015-04-22 | — | — | EP | claimed |
| WO-2013192225-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-12-27 | — | — | WO | claimed |
| WO-2013192229-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE - 5 - (6H) - ONE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-12-27 | — | — | WO | claimed |
| US-12521399-B2 | Compound as voltage-gated sodium channel inhibitor | GUANGZHOU FERMION TECHNOLOGY CO., LTD. (CN) | 2026-01-13 | — | — | US | disclosed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| EP-4570788-A1 | COMPOUND AS VOLTAGE-GATED SODIUM CHANNEL INHIBITOR | Guangzhou Fermion Technology Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-118406439-B | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-118406439-A | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024134947-A1 | MULTILAYER COATING FILM FORMATION METHOD | 日産自動車株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| CN-115028637-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| CN-117586180-A | Compounds useful as inhibitors of voltage-gated sodium channels | 广州费米子科技有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024032774-A1 | COMPOUND AS VOLTAGE-GATED SODIUM CHANNEL INHIBITOR | 广州费米子科技有限责任公司 | 2024-02-15 | — | — | WO | disclosed |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-12-26 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| CN-115093794-B | Polysilicon polishing composition and application thereof | 万华化学集团电子材料有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| CN-112047935-B | Autophagy targeting protein degradation technology and application thereof | 汪义朋 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023121378-A1 | (S)-2-(2-METHYLAZETIDIN-1-YL)PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 엘지화학 | 2023-06-29 | — | — | WO | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-4134368-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-15 | — | — | EP | disclosed |
| US-11555012-B2 | ACLY inhibitors and uses thereof | Nimbus Artemis, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-3331880-B3 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-01-11 | — | — | EP | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-113840885-B | Antifouling coating composition | 日东化成株式会社 | 2022-11-15 | — | — | CN | disclosed |
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | disclosed |
| EP-3399001-B1 | AQUEOUS COATING MATERIAL COMPOSITION AND COATING FILM FORMING METHOD | NIPPON PAINT AUTOMOTIVE COATINGS CO LTD (JP) | 2022-10-12 | — | — | EP | disclosed |
| CN-115093794-A | Polysilicon polishing composition and application thereof | 万华化学集团电子材料有限公司 | 2022-09-23 | — | — | CN | disclosed |
| EP-4059932-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115028636-A | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115028637-A | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| EP-3790879-B1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| CN-112469721-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022104636-A1 | AUTOPHAGIC TARGETED PROTEIN DEGRADATION TECHNIQUE AND USE THEREOF | 上海强睿生物科技有限公司 | 2022-05-27 | — | — | WO | disclosed |
| US-11312680-B2 | Method for treating a patient having a colon cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3978575-A1 | ANTIFOULING COATING COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2022-04-06 | — | — | EP | disclosed |
| US-11208381-B2 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| CN-113840885-A | Antifouling coating composition | 日东化成株式会社 | 2021-12-24 | — | — | CN | disclosed |
| US-20210395187-A1 | METHOD FOR TREATING A PATIENT HAVING A COLON CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-23 | — | — | US | disclosed |
| EP-3331880-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-12-01 | — | — | EP | disclosed |
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| EP-3331864-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | disclosed |
| US-11142493-B1 | Pharmaceutical composition for treating cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-12 | — | — | US | disclosed |
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| CN-108137518-B | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-08-31 | — | — | CN | disclosed |
| WO-2021160012-A1 | SMALL MOLECULAR COMPOUND SPECIFICALLY DEGRADING TAU PROTEIN AND USE THEREOF | 上海强睿生物科技有限公司 | 2021-08-19 | — | — | WO | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-11084827-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| CN-108883432-B | Method for forming multilayer coating film | 日涂汽车涂料有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113179590-A | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-109153666-B | Indole derivatives and their use as protein kinase inhibitors | 莱斯彼维特有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-107922362-B | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2021-06-15 | — | — | CN | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10988439-B2 | Cytotoxic compounds, pharmaceutical compositions thereof, and methods of treating cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2021-04-27 | — | — | US | disclosed |
| US-20210114982-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| CN-107208279-B | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3790879-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-03-17 | — | — | EP | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| EP-3786156-A1 | 10H-PHENOTHIAZINE FERROPTOSIS INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Chengdu Henghao Investment Co. Limited (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20210040079-A1 | 10H-phenothiazine ferroptosis inhibitor as well as the preparative method and the use thereof | Chengdu Henghao Investment Co. Limited (CN) | 2021-02-11 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3409378-B1 | METHOD FOR FORMING MULTILAYER COATING FILM | NIPPON PAINT AUTOMOTIVE COATINGS CO LTD (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-10870765-B2 | Aqueous coating composition and method for forming a coating film | NIPPON PAINT AUTOMOTIVE COATINGS CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20200385336-A1 | CYTOTOXIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATING CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2020-12-10 | — | — | US | disclosed |
| WO-2020241542-A1 | ANTIFOULING COATING COMPOSITION | 日東化成株式会社 | 2020-12-03 | — | — | WO | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| US-20200283639-A1 | AQUEOUS COATING COMPOSITION AND METHOD FOR FORMING A COATING FILM | NIPPON PAINT AUTOMOTIVE COATINGS CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
| EP-3426649-B1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| US-10696866-B2 | Method for forming multilayer coating film | NIPPON PAINT AUTOMOTIVE COATINGS CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10669235-B2 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10513523-B2 | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-24 | — | — | US | disclosed |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2019-11-19 | — | — | US | disclosed |
| WO-2019215316-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-20190345306-A1 | RECYCLING PROCESS | WORN AGAIN TECHNOLOGIES LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3288945-B1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-18 | — | — | EP | disclosed |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-09-05 | — | — | US | disclosed |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-2968316-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10329275-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| EP-3489238-A1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | Dart NeuroScience (Cayman) Ltd (KY) | 2019-05-29 | — | — | EP | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | disclosed |
| US-20190071399-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SYGNATURE DISCOVERY LTD (GB) | 2019-03-07 | — | — | US | disclosed |
| US-20190031915-A1 | METHOD FOR FORMING MULTILAYER COATING FILM | NIPPON PAINT AUTOMOTIVE COATINGS CO., LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20190031686-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | VALO EARLY DISCOVERY, INC. | 2019-01-31 | — | — | US | disclosed |
| EP-3426649-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Respivert Limited (GB) | 2019-01-16 | — | — | EP | disclosed |
| US-10174428-B2 | Etchant, replenishment solution and method for forming copper wiring | MEC COMPANY LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-2861603-B1 | 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-19 | — | — | EP | disclosed |
| EP-3409378-A1 | METHOD FOR FORMING MULTILAYER COATING FILM | Nippon Paint Automotive Coatings Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| EP-3399001-A1 | AQUEOUS COATING MATERIAL COMPOSITION AND COATING FILM FORMING METHOD | Nippon Paint Automotive Coatings Co., Ltd. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-10092575-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-10-09 | — | — | US | disclosed |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-06 | — | — | US | disclosed |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2018-08-09 | — | — | US | disclosed |
| EP-3354650-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2802576-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3328843-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-06 | — | — | EP | disclosed |
| US-9963452-B2 | Methods, compounds, and compositions for inhibition of ROS | AUGUSTA PHARMACEUTICALS INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963452-B2 | Methods, compounds, and compositions for inhibition of ROS | AUGUSTA PHARMACEUTICALS INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260632-A1 | ETCHANT, REPLENISHMENT SOLUTION AND METHOD FOR FORMING COPPER WIRING | MEC COMPANY LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
| WO-2017153748-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-09-14 | — | — | WO | disclosed |
| EP-3212201-A1 | NUCLEOSIDE KINASE INHIBITORS | BCI Pharma (FR) | 2017-09-06 | — | — | EP | disclosed |
| US-20170218162-A1 | RECYCLING PROCESS | WORN AGAIN TECHNOLOGIES LIMITED (GB) | 2017-08-03 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170209459-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9701674-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-9676721-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676721-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| EP-3172267-A1 | RECYCLING PROCESS | Worn Again Footwear And Accessories Limited (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| US-20170137441-A1 | Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT) | VALO EARLY DISCOVERY, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137441-A1 | Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT) | VALO EARLY DISCOVERY, INC. | 2017-05-18 | — | — | US | disclosed |
| EP-3022194-B1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2861605-B1 | 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2017-05-03 | — | — | EP | disclosed |
| US-9573957-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-21 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| WO-2017020065-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017018803-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-02-02 | — | — | WO | disclosed |
| US-9555039-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | FORMA TM, LLC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555039-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | FORMA TM, LLC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9499562-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-11-22 | — | — | US | disclosed |
| EP-2872504-B1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| WO-2016176457-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-10-27 | — | — | US | disclosed |
| EP-2885285-B1 | PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-10-19 | — | — | EP | disclosed |
| EP-2855472-B1 | NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE | BOEHRINGER INGELHEIM INT (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-2855472-B1 | NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE | BOEHRINGER INGELHEIM INT (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9365557-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
| EP-2611777-B1 | N-(4-{[PYRIDIN-3-YL-METHYL)CARBAMOYL]AMINO}BENZENE-SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM LLC (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2016066582-A1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2016-05-06 | — | — | WO | disclosed |
| US-9315499-B2 | Cytomegalovirus inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-9315499-B2 | Cytomegalovirus inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-9315499-B2 | Cytomegalovirus inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160083375-A1 | THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| US-9284335-B2 | Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-03-15 | — | — | US | disclosed |
| EP-2991982-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-03-09 | — | — | EP | disclosed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031890-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS | GRUENEBERG, Dorre A. | 2016-02-04 | — | — | US | disclosed |
| US-20160031890-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS | GRUENEBERG, Dorre A. | 2016-02-04 | — | — | US | disclosed |
| WO-2016012755-A1 | RECYCLING PROCESS | WORN AGAIN FOOTWEAR AND ACCESSORIES LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |
| US-9242976-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-9156937-B2 | Block polyisocyanate composition and coating composition containing same | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-10-13 | — | — | US | disclosed |
| CN-104955985-A | Etching solution, replenishment solution, and method for forming copper wiring | MEC CO LTD | 2015-09-30 | — | — | CN | disclosed |
| CN-104876893-A | Substituted-homopiperzine dithiocarbamic acid bismuth complexes, and medicinal salts, preparation methods and antitumor application thereof | UNIV NANYANG NORMAL | 2015-09-02 | — | — | CN | disclosed |
| EP-2611778-B1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015104353-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104356-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150158861-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158861-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158861-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| EP-2283004-B1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | UNIV EDINBURGH (GB) | 2015-05-27 | — | — | EP | disclosed |
| EP-2283004-B1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | UNIV EDINBURGH (GB) | 2015-05-27 | — | — | EP | disclosed |
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2861605-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2015-04-22 | — | — | EP | disclosed |
| EP-2855472-A1 | NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE | Boehringer Ingelheim International GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-8993563-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2842956-A1 | PARP inhibitor compounds, compositions and methods of use | Eisai Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-8952176-B2 | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20150031661-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2015009611-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| EP-2535364-B1 | BLOCK POLYISOCYANATE COMPOSITION AND COATING COMPOSITION CONTAINING SAME | ASAHI KASEI CHEMICALS CORP (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8921358-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8894989-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014141129-A9 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS | GRUENEBERG DORRE A (US) | 2014-11-06 | — | — | WO | disclosed |
| CN-102307869-B | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO.,LTD. (JP) | 2014-10-22 | — | — | CN | disclosed |
| WO-2014164749-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164767-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-2786995-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2786995-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8846647-B2 | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8841308-B2 | Pyrazin-2-amines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | disclosed |
| WO-2014141129-A2 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS | GRUENEBERG DORRE A (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140248240-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | VALO HEALTH, INC. | 2014-09-04 | — | — | US | disclosed |
| US-20140248240-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | VALO HEALTH, INC. | 2014-09-04 | — | — | US | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2523949-B1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8791103-B2 | Carboxylic acid amides, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| EP-2459551-B1 | DIHYDROBENZOINDAZOLES | MERCK SHARP & DOHME (NL) | 2014-07-02 | — | — | EP | disclosed |
| EP-2311837-B1 | Azaindoles useful as inhibitors of jak and other protein kinases | VERTEX PHARMA (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2311837-B1 | Azaindoles useful as inhibitors of jak and other protein kinases | VERTEX PHARMA (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140113005-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-24 | — | — | US | disclosed |
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| WO-2014009447-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013192225-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-12-27 | — | — | WO | disclosed |
| US-20130345197-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-26 | — | — | US | disclosed |
| US-8614209-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-12-24 | — | — | US | disclosed |
| US-20130336920-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | disclosed |
| US-8592463-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2013-11-26 | — | — | US | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8586748-B2 | 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2013152063-A1 | NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013152063-A1 | NAPHTHYRIDINONE DERIVATIVES AS INHIBITORS OF CYTOMEGALOVIRUS DNA POLYMERASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
| US-20130237522-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| EP-2634176-A1 | PYRIDINE DERIVATIVE AND MEDICINAL AGENT | Nippon Shinyaku Co., Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225555-A1 | Imidazoquinolines with Immuno-Modulating Properties | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225548-A1 | Pyridine Derivative and Medicinal Agent | NIPPON SHINYAKU CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130203731-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| US-8501446-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501446-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | disclosed |
| US-8461163-B2 | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8445525-B2 | Carboxylic acid amides, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| EP-2591354-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590656-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8436178-B2 | Imidazoquinolines with immuno-modulating properties | ASTRAZENECA AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8394789-B2 | (Dihydro)pyrrolo[2,1-α]isoquinolines | MSD OSS B.V. (NL) | 2013-03-12 | — | — | US | disclosed |
| US-8383620-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130012545-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130005696-A1 | BUFADIENOLIDE DERIVATIVES, PREPARING PROCESS THEREOF, COMPOSITION COMPRISING THE SAME AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-01-03 | — | — | US | disclosed |
| US-20130005696-A1 | BUFADIENOLIDE DERIVATIVES, PREPARING PROCESS THEREOF, COMPOSITION COMPRISING THE SAME AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-01-03 | — | — | US | disclosed |
| EP-2535364-A1 | BLOCK POLYISOCYANATE COMPOSITION AND COATING COMPOSITION CONTAINING SAME | Asahi Kasei Chemicals Corporation (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20120316291-A1 | BLOCK POLYISOCYANATE COMPOSITION AND COATING COMPOSITION CONTAINING SAME | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2012-12-13 | — | — | US | disclosed |
| WO-2012154194-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | FORMA TM, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-2518074-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| EP-2332940-B1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMA (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299063-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-8273890-B2 | Thiophene-imidazopyridines | 4SC AG (DE) | 2012-09-25 | — | — | US | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| EP-2155743-B1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2012-08-29 | — | — | EP | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2459551-A1 | DIHYDROBENZOINDAZOLES | MSD Oss B.V. (NL) | 2012-06-06 | — | — | EP | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| EP-2430024-A1 | [1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | AstraZeneca AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031199-A1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2403847-A1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-01-11 | — | — | EP | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-8071589-B2 | Dihydrobenzoindazoles | N. V. ORGANON (NL) | 2011-12-06 | — | — | US | disclosed |
| US-8071589-B2 | Dihydrobenzoindazoles | N. V. ORGANON (NL) | 2011-12-06 | — | — | US | disclosed |
| US-8071589-B2 | Dihydrobenzoindazoles | N. V. ORGANON (NL) | 2011-12-06 | — | — | US | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275800-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2370424-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2252611-B1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| EP-2252611-B1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1771441-B1 | NOVEL CARBOXAMIDES FOR USE AS XA INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| WO-2011086099-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2332940-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-7947700-B2 | Factor Xa or related serine protease inhibitors; such as 3-chloro-N-[1-(5-chloro-1H-benzimidazol-2-yl)-ethyl]-4-(1,4-diazepan-1-yl)benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-1730146-B1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-2311837-A1 | Azaindoles useful as inhibitors of jak and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2011000945-A9 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082151-A1 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077236-A1 | NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110039832-A1 | DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2011-02-17 | — | — | US | disclosed |
| EP-2283004-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-7888352-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIRAMED LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| WO-2011012674-A1 | DIHYDROBENZOINDAZOLES | N.V. ORGANON (NL) | 2011-02-03 | — | — | WO | disclosed |
| US-20110028451-A1 | Dihydrobenzoindazoles | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
| US-20110028451-A1 | Dihydrobenzoindazoles | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
| US-20110028451-A1 | Dihydrobenzoindazoles | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
| EP-2276731-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | Boehringer Ingelheim International GmbH (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2011-01-20 | — | — | US | disclosed |
| EP-2271646-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| WO-2011000945-A2 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010149684-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| EP-2252611-A1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. Organon (NL) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| EP-2249646-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| EP-2227456-A2 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | Siena Biotech S.p.A. (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| WO-2010100405-A1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-09-10 | — | — | WO | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| EP-2209375-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Eisai Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010077992-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010071837-A1 | PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010054398-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2155743-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| EP-2118105-A1 | PURINE DERIVATIVES | Palau Pharma, S.A. (ES) | 2009-11-18 | — | — | EP | disclosed |
| EP-2114949-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| WO-2009126675-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009123986-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009100169-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100169-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098283-A1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098283-A1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2009-08-13 | — | — | WO | disclosed |
| EP-1457488-B1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2009091832-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091832-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091831-A1 | COMPOUND FORMS AND USES THEREOF | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091831-A1 | COMPOUND FORMS AND USES THEREOF | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091813-A1 | COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091433-A2 | SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181953-A1 | COMPOUND FORMS AND USES THEREOF | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181953-A1 | COMPOUND FORMS AND USES THEREOF | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181953-A1 | COMPOUND FORMS AND USES THEREOF | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181952-A1 | COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| WO-2009074300-A2 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2009-06-18 | — | — | WO | disclosed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MGI GP, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2046783-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009046205-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI RESEARCH INSTITUTE (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | disclosed |
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2008135791-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008090181-A1 | PURINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2008-07-31 | — | — | WO | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080146539-A1 | NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-7371743-B2 | Carboxylic acid amides, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-7351700-B2 | Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1643998-B1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| EP-1417184-B1 | COMPOSITION FOR DYEING KERATINOUS FIBRES CONTAINING A PARAPHENYLENEDIAMINE SUBSTITUTED BY A DIAZACYCLOHEPTANE RADICAL | OREAL (FR) | 2007-08-29 | — | — | EP | disclosed |
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1812407-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | Pfizer, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1725239-B1 | 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY | HOFFMANN LA ROCHE (CH) | 2007-07-18 | — | — | EP | disclosed |
| US-7241317-B2 | Composition for dyeing keratin fibers comprising at least one para-phenylenediamine substituted with a diazacycloheptane radical | L'OREAL, S.A. (FR) | 2007-07-10 | — | — | US | disclosed |
| US-7241317-B2 | Composition for dyeing keratin fibers comprising at least one para-phenylenediamine substituted with a diazacycloheptane radical | L'OREAL, S.A. (FR) | 2007-07-10 | — | — | US | disclosed |
| US-7241317-B2 | Composition for dyeing keratin fibers comprising at least one para-phenylenediamine substituted with a diazacycloheptane radical | L'OREAL, S.A. (FR) | 2007-07-10 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7217447-B2 | Ink-jet recording sheet | FUJIFILM CORPORATION (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20070066585-A1 | ARYL PHENYLHETEROCYCLYL SULFIDE DERIVATIVES AND THEIR USE AS CELL ADHESION-INHIBITING ANTI-INFLAMMATORY AND IMMUNE-SUPPRESSIVE AGENTS | WANG GARY T | 2007-03-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| EP-1730146-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1725239-A1 | 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| US-7129247-B2 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-RE39197-E1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060135571-A1 | Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones | AEGERA THERAPEUTICS, INC. (CA) | 2006-06-22 | — | — | US | disclosed |
| US-7060836-B2 | Lactams as tachykinin antagonists | PFIZER, INC (US) | 2006-06-13 | — | — | US | disclosed |
| WO-2006048750-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1643998-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-6982260-B1 | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes | WARNER-LAMBERT COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| WO-2005094828-A1 | 4- (SULFANYL-PYRIMIDIN-4-YLMETHYL) -MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095400-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050203078-A1 | Inhibitors of factor Xa or related serine proteases; thrombosis; benzamide derivatives with benzimidazole, indole or imidazo(1,2-a)pyridine rings; e.g. 4-(azepan-2-on-1-yl)-N-[(1R)-1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxy-ethyl]-3-methyl-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| US-20050197337-A1 | Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050102769-A1 | Composition for dyeing keratinous fibers containing a paraphenylenediamine substituted by a diazacycloheptane radical | L'OREAL S.A. (FR) | 2005-05-19 | — | — | US | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | disclosed |
| US-6867203-B2 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-03-15 | — | — | US | disclosed |
| US-20050026929-A1 | Novel phenyl derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050014746-A1 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-supressive agents | ICOS CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| EP-1481968-A2 | Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds | Abbott Laboratories (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1456200-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-6787542-B2 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents | ICOS CORPORATION | 2004-09-07 | — | — | US | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| WO-2003051868-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| EP-1294704-A1 | ARYL PHENYLHETEROCYCLYL SULFIDE DERIVATIVES AND THEIR USE AS CELL ADHESION-INHIBITING ANTI-INFLAMMATORY AND IMMUNE-SUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020132807-A1 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents | ICOS CORPORATION | 2002-09-19 | — | — | US | disclosed |
| EP-1235815-A1 | QUINAZOLINES AND THEIR USE FOR INHIBITING CYCLIN-DEPENDENT KINASE ENZYMES | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6407103-B2 | POTENT ENZYME INHIBITORS OF CYCLIN-DEPENDENT KINASES RELATING TO THE CATALYTIC SUBUNITS CDK1-9 AND THEIR REGULATORY SUBUNITS CYCLINS A-H; ANTIPROLIFERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; VIRICIDES; MODULATORS OF DNA/RNA BIOSYNTHESIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-18 | — | — | US | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2002002539-A1 | ARYL PHENYLHETEROCYCLYL SULFIDE DERIVATIVES AND THEIR USE AS CELL ADHESION-INHIBITING ANTI-INFLAMMATORY AND IMMUNE-SUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1165505-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1140814-A2 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | DUPONT PHARMACEUTICALS COMPANY | 2001-10-04 | — | — | US | disclosed |
| WO-2001038315-A1 | QUINAZOLINES AND THEIR USE FOR INHIBITING CYCLIN-DEPENDENT KINASE ENZYMES | WARNER-LAMBERT COMPANY (US) | 2001-05-31 | — | — | WO | disclosed |
| JP-2001106676-A | PRODUCTION OF N-ACETYLHOMOPIPERAZINE | TOSOH CORP | 2001-04-17 | — | — | JP | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000059880-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-10-12 | — | — | WO | disclosed |
| US-6110922-A | ARYL SULFIDE CONTAINING PENDANT CIS- OR TRANS-CINNAMIDE GROUPS | ABBOTT LABORATORIES (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000039081-A2 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5661148-A | ANTIHYPOXIC AGENT FOR RESPIRATORY SYSTEM DISORDER | TEIJIN LIMITED (JP) | 1997-08-26 | — | — | US | disclosed |
| EP-0514540-B1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LTD (JP) | 1996-07-17 | — | — | EP | disclosed |
| EP-0514540-A1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1992-11-25 | — | — | EP | disclosed |
| EP-0514540-A1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1992-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | GSK3B, GSK3A, MAPT | CA2 2033/4885CHKA 317/4885CA12 4397/4885 |
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | CDK1, CCNA1, CDK19 | CA2 909/4885CHKA 675/4885CA12 3362/4885 |
| US-20210040079-A1 | 10H-phenothiazine ferroptosis inhibitor as well as the preparative method and the use thereof | AIFM2, FECH, GPX4 | CA2 2427/4885CHKA 4307/4885CA12 3796/4885 |
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | IFNG, FCGRT, IFNAR1 | CA2 3387/4885CHKA 2605/4885CA12 3938/4885 |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | CA2 4679/4885CHKA 2651/4885CA12 4830/4885 |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | CA2 1644/4885CHKA 3364/4885CA12 2172/4885 |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CA2 3961/4885CHKA 577/4885CA12 4367/4885 |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | HSD11B1, HSD11B2, HSD17B11 | CA2 1400/4885CHKA 3244/4885CA12 1172/4885 |
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CA2 4588/4885CHKA 811/4885CA12 4215/4885 |
| US-20210395187-A1 | METHOD FOR TREATING A PATIENT HAVING A COLON CANCER | TUBB1, TUBA1C, TUBB | CA2 2889/4885CHKA 267/4885CA12 2209/4885 |
| US-20020132807-A1 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents | VCAM1, ICAM1, CD47 | CA2 4583/4885CHKA 3519/4885CA12 4666/4885 |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIK5, GRIN1, GRIN3A | CA2 1488/4885CHKA 1496/4885CA12 4110/4885 |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CA2 2139/4885CHKA 549/4885CA12 3745/4885 |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | CA2 3961/4885CHKA 577/4885CA12 4367/4885 |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | CA2 1021/4885CHKA 3472/4885CA12 2745/4885 |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | AR, NR5A1, KLK3 | CA2 1328/4885CHKA 966/4885CA12 1287/4885 |
| US-20050014746-A1 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-supressive agents | ICAM1, VCAM1, CD47 | CA2 4588/4885CHKA 3317/4885CA12 4708/4885 |
| US-20050197337-A1 | Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors | CHRNA2, CNR2, GABRB2 | CA2 943/4885CHKA 2786/4885CA12 2196/4885 |
| US-11084827-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | CA2 1021/4885CHKA 3472/4885CA12 2745/4885 |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CA2 3923/4885CHKA 1296/4885CA12 4611/4885 |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | CA2 1515/4885CHKA 3247/4885CA12 2541/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CA2 3961/4885CHKA 577/4885CA12 4367/4885 |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | CA2 1021/4885CHKA 3472/4885CA12 2745/4885 |
| US-10092575-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | TPMT, PSEN2, GRIN2C | CA2 4305/4885CHKA 3241/4885CA12 4020/4885 |
| US-10669235-B2 | Indole derivatives and their use as protein kinase inhibitors | GRK3, IDO1, CIT | CA2 2051/4885CHKA 276/4885CA12 4470/4885 |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | CA2 653/4885CHKA 1586/4885CA12 1840/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CA2 4599/4885CHKA 847/4885CA12 4193/4885 |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | MC2R, AGTR2, AGTR1 | CA2 524/4885CHKA 2949/4885CA12 2423/4885 |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | CA2 203/4885CHKA 3431/4885CA12 1609/4885 |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | CA2 1375/4885CHKA 2131/4885CA12 2144/4885 |
| US-20130203731-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | CA2 3611/4885CHKA 1074/4885CA12 4810/4885 |
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | CA2 3689/4885CHKA 706/4885CA12 4472/4885 |
| US-20100204187-A1 | Purine Derivatives | JAK3, JAK1, JAK2 | CA2 4678/4885CHKA 1376/4885CA12 4865/4885 |
| US-20130005696-A1 | BUFADIENOLIDE DERIVATIVES, PREPARING PROCESS THEREOF, COMPOSITION COMPRISING THE SAME AND THE USE THEREOF | CYP11B1, CYP51A1, U2AF1 | CA2 4491/4885CHKA 4420/4885CA12 3086/4885 |
| US-20200385336-A1 | CYTOTOXIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATING CANCER | SRC, MCL1, LYN | CA2 2420/4885CHKA 106/4885CA12 3603/4885 |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | CA2 4742/4885CHKA 883/4885CA12 4830/4885 |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | CA2 2510/4885CHKA 555/4885CA12 4536/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | CA2 1351/4885CHKA 2898/4885CA12 200/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | CA2 4474/4885CHKA 1100/4885CA12 4665/4885 |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | CA2 1417/4885CHKA 874/4885CA12 1120/4885 |
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | CA2 1021/4885CHKA 3472/4885CA12 2745/4885 |
| US-11208381-B2 | Indole derivatives and their use as protein kinase inhibitors | GRK3, IDO1, CIT | CA2 2051/4885CHKA 276/4885CA12 4470/4885 |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | CA2 3497/4885CHKA 3772/4885CA12 4660/4885 |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | CA2 1310/4885CHKA 187/4885CA12 4433/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CA2 4588/4885CHKA 811/4885CA12 4215/4885 |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CA2 3923/4885CHKA 1296/4885CA12 4611/4885 |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CA2 1384/4885CHKA 2754/4885CA12 2746/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | CA2 203/4885CHKA 3431/4885CA12 1609/4885 |
| US-20120316291-A1 | BLOCK POLYISOCYANATE COMPOSITION AND COATING COMPOSITION CONTAINING SAME | AKR1B1, AKR1A1, KYAT1 | CA2 1116/4885CHKA 1062/4885CA12 981/4885 |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | CA2 2943/4885CHKA 1423/4885CA12 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.